David M Kaye

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9124105/publications.pdf

Version: 2024-02-01

399 papers	26,918 citations	4955 84 h-index	8156 148 g-index
413 all docs	413 docs citations	413 times ranked	26682 citing authors

#	Article	IF	Citations
1	Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure Snapshot. Heart Lung and Circulation, 2022, 31, 623-628.	0.2	10
2	The Use of Mobile Apps for Heart Failure Self-management: Systematic Review of Experimental and Qualitative Studies. JMIR Cardio, 2022, 6, e33839.	0.7	17
3	Incidence and Outcomes of Nontraumatic Shock in Adults Using Emergency Medical Services in Victoria, Australia. JAMA Network Open, 2022, 5, e2145179.	2.8	9
4	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	6.3	112
5	A gold nanowire-integrated soft wearable system for dynamic continuous non-invasive cardiac monitoring. Biosensors and Bioelectronics, 2022, 205, 114072.	5.3	15
6	Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges. Heart Lung and Circulation, 2022, 31, 616-622.	0.2	5
7	Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients. JACC Basic To Translational Science, 2022, 7, 116-127.	1.9	20
8	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation, 2022, 145, 1592-1604.	1.6	54
9	Association of Socioeconomic Status With Outcomes and Care Quality in Patients Presenting With Undifferentiated Chest Pain in the Setting of Universal Health Care Coverage. Journal of the American Heart Association, 2022, 11, e024923.	1.6	9
10	Determinants of Undertaking Coronary Angiography and Adverse Prognostic Predictors Among Patients Presenting With Out-of-Hospital Cardiac Arrest and a Shockable Rhythm. American Journal of Cardiology, 2022, 171, 75-83.	0.7	5
11	Vasoplegia Following Orthotopic Heart Transplantation: Prevalence, Predictors and Clinical Outcomes. Journal of Cardiac Failure, 2022, 28, 617-626.	0.7	15
12	Diagnosis and management of arrhythmias in pregnancy. Europace, 2022, 24, 1041-1051.	0.7	4
13	Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, , .	1.7	1
14	Physiologic Insights Into Long COVID Breathlessness. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009346.	1.6	0
15	Incidence, diagnoses and outcomes of ambulance attendances for chest pain: a population-based cohort study. Annals of Epidemiology, 2022, 72, 32-39.	0.9	9
16	Venous Tone and Stressed Blood Volume in HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 1858-1869.	1.2	35
17	Development and validation of a comprehensive early risk prediction model for patients with undifferentiated acute chest pain. IJC Heart and Vasculature, 2022, 40, 101043.	0.6	2
18	Measurement of Noradrenaline and Serotonin Metabolites With Internal Jugular Vein Sampling: An Indicator of Brain Monoamine Turnover in Depressive Illness and Panic Disorder. Frontiers in Psychiatry, 2022, 13, .	1.3	2

#	Article	IF	Citations
19	Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea. JAMA Cardiology, 2022, 7, 891.	3.0	43
20	Association Between the Gut Microbiome and Their Metabolites With Human Blood Pressure Variability. Hypertension, 2022, 79, 1690-1701.	1.3	11
21	Gender Disparities in Cardiogenic Shock Treatment and Outcomes. American Journal of Cardiology, 2022, 177, 14-21.	0.7	9
22	Multimorbidity and multiple causes of death in heart failure. Zeitschrift Fur Gesundheitswissenschaften, 2021, 29, 1181-1187.	0.8	0
23	Impact of a model of care for heart failure inâ€patients to reduce variation in care: a quality improvement project. Internal Medicine Journal, 2021, 51, 557-564.	0.5	3
24	Previous Pre-Eclampsia, Gestational Diabetes and Hypertension Place Women at High Cardiovascular Risk: But Do We Ask?. Heart Lung and Circulation, 2021, 30, 154-157.	0.2	8
25	Gender Differences in Healthy Lifestyle Adherence Following Percutaneous Coronary Intervention for Coronary Artery Disease. Heart Lung and Circulation, 2021, 30, e37-e40.	0.2	14
26	Part 1: The Wider Considerations in Translating Heart Failure Guidelines. Current Cardiology Reviews, 2021, 17, e160721190003.	0.6	2
27	Design, Development, In Vitro and Preliminary In Vivo Evaluation of a Novel Photo-Angioplasty Device: Lumi-Solve. Cardiovascular Engineering and Technology, 2021, 12, 466-473.	0.7	1
28	The results of a single-center experience with HeartMate 3 in a biventricular configuration. Journal of Heart and Lung Transplantation, 2021, 40, 193-200.	0.3	33
29	Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 754-764.	2.9	19
30	A prospective <scp>STudy</scp> using <scp>invAsive</scp> haemodynamic measurements <scp>foLLowing</scp> catheter ablation for <scp>AF</scp> and early <scp>HFpEF</scp>: <scp>STALL AFâ€HFpEF</scp>. European Journal of Heart Failure, 2021, 23, 785-796.	2.9	43
31	Oral Milrinone for the Treatment of Chronic Severe Right Ventricular Failure in Left Ventricular Assist Device Patients. Circulation: Heart Failure, 2021, 14, e007286.	1.6	7
32	Prone and Supine 12-Lead ECGÂComparisons. JACC: Clinical Electrophysiology, 2021, 7, 1348-1357.	1.3	7
33	Renal ACE2 (Angiotensin-Converting Enzyme 2) Expression Is Modulated by Dietary Fiber Intake, Gut Microbiota, and Their Metabolites. Hypertension, 2021, 77, e53-e55.	1.3	9
34	Microbial Interventions to Control and Reduce Blood Pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial. Trials, 2021, 22, 496.	0.7	17
35	The Gut Microbiome of Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e020654.	1.6	59
36	Treating symptoms and reversing remodelling: clinical and echocardiographic <scp>1â€year</scp> outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1971-1978.	2.9	10

#	Article	IF	Citations
37	Dihydrosphingosine driven enrichment of sphingolipids attenuates TGFÎ² induced collagen synthesis in cardiac fibroblasts. IJC Heart and Vasculature, 2021, 35, 100837.	0.6	3
38	Essential Hypertension Is Associated With Changes in Gut Microbial Metabolic Pathways: A Multisite Analysis of Ambulatory Blood Pressure. Hypertension, 2021, 78, 804-815.	1.3	42
39	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. Journal of the American Heart Association, 2021, 10, e021584.	1.6	12
40	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. Vascular Pharmacology, 2021, 141, 106923.	1.0	4
41	Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2021, 156, 52-57.	0.7	3
42	Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition. Toxicology Letters, 2021, 350, 133-142.	0.4	7
43	The Gut Microbiota and Their Metabolites in Human Arterial Stiffness. Heart Lung and Circulation, 2021, 30, 1716-1725.	0.2	12
44	The adrenal medulla in cardiovascular medicine: an untold story. Journal of Hypertension, 2021, 39, 819-829.	0.3	6
45	Comparison of Circulatory Unloading Techniques for Venoarterial Extracorporeal Membrane Oxygenation. ASAIO Journal, 2021, 67, 623-631.	0.9	10
46	Reply to â€˜Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitationâ€™. European Journal of Heart Failure, 2021, 23, 1985-1986.	2.9	1
47	Association between pre-hospital chest pain severity and myocardial injury in ST elevation myocardial infarction: A post-hoc analysis of the AVOID study. IJC Heart and Vasculature, 2021, 37, 100899.	0.6	0
48	Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!. European Respiratory Journal, 2021, 58, 2101839.	3.1	0
49	The prognostic significance of chronotropic incompetence in patients with severe left ventricular systolic function referred for cardiac transplant assessment. European Journal of Preventive Cardiology, 2020, 27, 328-330.	0.8	1
50	Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart, 2020, 106, 58-68.	1.2	69
51	The Baker Biobank: Understanding Cardiovascular Outcomes. Heart Lung and Circulation, 2020, 29, 1071-1077.	0.2	3
52	Non-invasive blood pressure monitoring underestimates hypertensive response to exercise in suspected heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2020, 27, 2180-2182.	0.8	1
53	Alcohol Abstinence in Drinkers with Atrial Fibrillation. New England Journal of Medicine, 2020, 382, 20-28.	13.9	254
54	Relationship of Degree of Systolic Dysfunction to Variations in Exercise Capacity and Hemodynamic Status inÂHFpEF. JACC: Cardiovascular Imaging, 2020, 13, 528-530.	2.3	3

#	Article	IF	Citations
55	Manipulation of the gut microbiota by the use of prebiotic fibre does not override a genetic predisposition to heart failure. Scientific Reports, 2020, 10, 17919.	1.6	8
56	Characterization of infected, explanted ventricular assist device drivelines: The role of biofilms and microgaps in the driveline tunnel. Journal of Heart and Lung Transplantation, 2020, 39, 1289-1299.	0.3	9
57	Prehospital opioid dose and myocardial injury in patients with ST elevation myocardial infarction. Open Heart, 2020, 7, e001307.	0.9	12
58	Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 3685-3693.	1.4	9
59	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. Journal of the American Heart Association, 2020, 9, e016760.	1.6	19
60	The Effect of Transitional Care on 30-Day Outcomes in Patients Hospitalised With Acute Heart Failure. Heart Lung and Circulation, 2020, 29, 1347-1355.	0.2	15
61	COVID-19 and Acute Heart Failure: Screening the Critically Ill â€“ A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ). Heart Lung and Circulation, 2020, 29, e94-e98.	0.2	17
62	The Emerging Role of Gut Dysbiosis in Cardio-metabolic Risk Factors for Heart Failure. Current Hypertension Reports, 2020, 22, 38.	1.5	19
63	Device Based Approaches to the Prevention of Contrast-Induced Acute Kidney Injury. Interventional Cardiology Clinics, 2020, 9, 395-401.	0.2	0
64	Extendedâ€Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2020, 9, e015026.	1.6	30
65	Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease. Circulation, 2020, 141, 1393-1403.	1.6	176
66	Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon Device. Cardiovascular Revascularization Medicine, 2020, 21, 712-716.	0.3	14
67	The effect of parity on exercise physiology in women with heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 214-223.	1.4	3
68	Exogenous dihydrosphingosine 1 phosphate mediates collagen synthesis in cardiac fibroblasts through JAK/STAT signalling and regulation of TIMP1. Cellular Signalling, 2020, 72, 109629.	1.7	15
69	Optimal Mechanical Unloading in Left Ventricular Assist Device Recipients Relates to Progressive Up-Titration in Pump Speed. Journal of the American Society of Echocardiography, 2020, 33, 583-593.	1.2	4
70	Cardiorenal syndrome: Multiâ€organ dysfunction involving the heart, kidney and vasculature. British Journal of Pharmacology, 2020, 177, 2906-2922.	2.7	46
71	High-intensity interval training in patients with left ventricular assist devices: A pilot randomized controlled trial. Journal of Heart and Lung Transplantation, 2020, 39, 1380-1388.	0.3	10
72	Endothelial-specific overexpression of cationic amino acid transporter-1 prevents loss of kidney function in heart failure. Clinical Science, 2020, 134, 2755-2769.	1.8	2

#	Article	IF	Citations
73	Management of heart failure with preserved ejection fraction. Australian Prescriber, 2020, 43, 12-17.	0.5	6
74	Selective Recertification of Pilots Who Have Undergone a Cardiac Transplant. Aerospace Medicine and Human Performance, 2020, 91, 732-736.	0.2	0
75	Reply. JACC: Heart Failure, 2019, 7, 535-536.	1.9	0
76	Impact of Sex on Ventricularâ€Vascular Stiffness and Longâ€Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy. Journal of the American Heart Association, 2019, 8, e012190.	1.6	18
77	Electrical Phenotype in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 428-430.	1.9	0
78	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). American Journal of Cardiology, 2019, 124, 1912-1917.	0.7	13
79	Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 143.	1.1	16
80	A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction. Progress in Transplantation, 2019, 29, 327-334.	0.4	0
81	The REDUCE FMR Trial. JACC: Heart Failure, 2019, 7, 945-955.	1.9	106
82	Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 495-505.	2.9	108
83	Venoarterial extracorporeal membrane oxygenation: A systematic review of selection criteria, outcome measures and definitions of complications. Journal of Critical Care, 2019, 53, 32-37.	1.0	23
84	Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2019, 73, 2846-2855.	1.2	27
85	Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart, 2019, 6, e001012.	0.9	56
86	The role of the gut microbiome in sex differences in arterial pressure. Biology of Sex Differences, 2019, 10, 22.	1.8	44
87	Pathophysiology of Atrial Fibrillation and Heart Failure. Cardiology Clinics, 2019, 37, 131-138.	0.9	34
88	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	1.9	33
89	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet, The, 2019, 393, 1045-1055.	6.3	48
90	Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: underpinning intracellular targets for cardiorenal syndrome therapy. Toxicology Letters, 2019, 308, 34-49.	0.4	12

#	Article	IF	Citations
91	CXCR4 Antagonism Reduces Cardiac Fibrosis and Improves Cardiac Performance in Dilated Cardiomyopathy. Frontiers in Pharmacology, 2019, 10, 117.	1.6	13
92	Sex Differences in Heart Failure WithÂPreserved Ejection FractionÂPathophysiology. JACC: Heart Failure, 2019, 7, 239-249.	1.9	82
93	Resting and Exercise Doppler Hemodynamics. Heart Failure Clinics, 2019, 15, 229-239.	1.0	1
94	The gut microbiota and blood pressure in experimental models. Current Opinion in Nephrology and Hypertension, 2019, 28, 97-104.	1.0	44
95	Effects of Interatrial Shunt on Pulmonary Vascular Function in HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2539-2550.	1.2	69
96	A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia. Cardiovascular Drugs and Therapy, 2019, 33, 687-692.	1.3	3
97	Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c.	1.0	406
98	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 2019, 6, 62-69.	1.4	45
99	Comparison of Magnetic Resonance Analysis of Myocardial Scarring With Biomarker Release Following S-T Elevation Myocardial Infarction. Heart Lung and Circulation, 2019, 28, 397-405.	0.2	7
100	Impaired <scp>l</scp>-arginine-nitric oxide pathway contributes to the pathogenesis of resistant hypertension. Clinical Science, 2019, 133, 2061-2067.	1.8	14
101	Implications of Underlying Mechanisms forÂthe Recognition and Management of Diabetic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 339-351.	1.2	235
102	Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681775160.	0.6	23
103	Double jeopardy: Competing arrhythmias in heterotopic heart transplants. Journal of Heart and Lung Transplantation, 2018, 37, 936-938.	0.3	1
104	Resting and exercise haemodynamics in relation to sixâ€minute walk test in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 715-722.	2.9	41
105	Inverse Association Between Myocardial B-Type Natriuretic Peptide Release and Functional Capacity in Healthy Humans. Heart Lung and Circulation, 2018, 27, 995-1003.	0.2	3
106	Beyond gut feelings: how the gut microbiota regulates blood pressure. Nature Reviews Cardiology, 2018, 15, 20-32.	6.1	287
107	The ageing heart: the systemic and coronary circulation. Heart, 2018, 104, 370-376.	1.2	30
108	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]). Circulation, 2018, 137, 364-375.	1.6	206

#	Article	IF	Citations
109	Comparison of Commonly Used Questionnaires to Identify Obstructive Sleep Apnea in a High-Risk Population. Journal of Clinical Sleep Medicine, 2018, 14, 2057-2064.	1.4	18
110	Subclinical Left Ventricular Dysfunction is Influenced by Genotype Severity in Patients with Cystic Fibrosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2018, 12, 117954841879415.	0.5	8
111	Population-Based Gut Microbiome Associations With Hypertension. Circulation Research, 2018, 123, 1185-1187.	2.0	6
112	Characterising risk of in-hospital mortality following cardiac arrest using machine learning: A retrospective international registry study. PLoS Medicine, 2018, 15, e1002709.	3.9	85
113	Exercise training in heart failure: a long way to go yet. European Journal of Heart Failure, 2018, 20, 1744-1745.	2.9	8
114	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e004540.	1.6	23
115	Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy. Experimental Physiology, 2018, 103, 1593-1602.	0.9	10
116	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968.	3.0	121
117	Extended Release Oral Milrinone, CRD-102, for Advanced Heart Failure. American Journal of Cardiology, 2018, 122, 1017-1020.	0.7	21
118	Regression of Diffuse Ventricular FibrosisÂFollowing Restoration of SinusÂRhythm With Catheter Ablation inÂPatients With Atrial Fibrillation andÂSystolic Dysfunction. JACC: Clinical Electrophysiology, 2018, 4, 999-1007.	1.3	39
119	Age-Related Differential Structural and Transcriptomic Responses in the Hypertensive Heart. Frontiers in Physiology, 2018, 9, 817.	1.3	6
120	Sex Differences in Cardiovascular Pathophysiology. Circulation, 2018, 138, 198-205.	1.6	302
121	Enhancing selfâ€care strategies in heart failure through patientâ€reported outcome measures. Internal Medicine Journal, 2018, 48, 995-998.	0.5	17
122	Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Scientific Reports, 2018, 8, 8213.	1.6	42
123	Understanding the Role of the LA in Functional Responses to HeartÂFailure. JACC: Cardiovascular Imaging, 2017, 10, 1265-1267.	2.3	1
124	Impaired Right Heart and Pulmonary Vascular Function in HFpEF. JACC: Cardiovascular Imaging, 2017, 10, 1222-1224.	2.3	8
125	The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy. European Journal of Pharmacology, 2017, 807, 12-20.	1.7	39
126	Cardiac Gene Delivery Using Recirculating Devices. Methods in Molecular Biology, 2017, 1521, 261-269.	0.4	1

#	Article	IF	Citations
127	Exercise Hemodynamics as a Predictor of Myocardial Recovery in LVAD Patients. ASAIO Journal, 2017, 63, 342-345.	0.9	5
128	Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. Diabetes and Vascular Disease Research, 2017, 14, 423-433.	0.9	35
129	Cardiac magnetic resonance imaging in suspected blunt cardiac injury: A prospective, pilot, cohort study. Injury, 2017, 48, 1013-1019.	0.7	12
130	A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failureâ€"Trial design of the REDUCE FMR study. American Heart Journal, 2017, 188, 167-174.	1.2	34
131	High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation, 2017, 135, 964-977.	1.6	695
132	Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age. Journal of the American Heart Association, 2017, 6, .	1.6	13
133	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697.	2.9	34
134	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications, 2017, 8, 14232.	5.8	104
135	Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. Journal of the American College of Cardiology, 2017, 70, 1949-1961.	1.2	428
136	Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. Heart Lung and Circulation, 2017, 26, 934-940.	0.2	13
137	Extended release oral milrinone as an adjunct to heart failure therapy. Internal Medicine Journal, 2017, 47, 973-974.	0.5	1
138	Atrial Fibrillation and Heart Failure â€" Cause or Effect?. Heart Lung and Circulation, 2017, 26, 967-974.	0.2	72
139	N-Acetylcysteine AttenuatesÂthe Development of Renal Fibrosis in Transgenic Mice with Dilated Cardiomyopathy. Scientific Reports, 2017, 7, 17718.	1.6	8
140	Point mutations in murine Nkx2-5 phenocopy human congenital heart disease and induce pathogenic Wnt signaling. JCI Insight, 2017, 2, e88271.	2.3	24
141	Effects of Dietary l-Arginine on Nitric Oxide Bioavailability in Obese Normotensive and Obese Hypertensive Subjects. Nutrients, 2016, 8, 364.	1.7	3
142	Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2016, 27, 571-580.	0.8	56
143	The transcardiac gradient of cardioâ€‹<scp>microRNAs</scp> in the failing heart. European Journal of Heart Failure, 2016, 18, 1000-1008.	2.9	151
144	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	113

#	Article	IF	Citations
145	N-terminal domain of Bothrops asper Myotoxin II Enhances the Activity of Endothelin Converting Enzyme-1 and Neprilysin. Scientific Reports, 2016, 6, 22413.	1.6	8
146	Relationships Among Cognitive Function and Cerebral Blood Flow, Oxidative Stress, and Inflammation in Older Heart Failure Patients. Journal of Cardiac Failure, 2016, 22, 548-559.	0.7	30
147	Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 67, 2554-2556.	1.2	28
148	Say NO to Obesity-Related Hypertension. Hypertension, 2016, 67, 813-819.	1.3	29
149	Role of Renal Oxidative Stress in the Pathogenesis of the Cardiorenal Syndrome. Heart Lung and Circulation, 2016, 25, 874-880.	0.2	41
150	N- acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure. Physiological Reports, 2016, 4, e12757.	0.7	37
151	Ventriculoarterial Coupling and the Diagnosis of Early LV Dysfunction âˆ—. JACC: Cardiovascular Imaging, 2016, 9, 1142-1144.	2.3	0
152	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	51
153	Biomarker validation of cardiac magnetic resonance analysis of regional myocardial fibrosis in ischaemic heart disease. Journal of Cardiovascular Magnetic Resonance, 2016, 18, P77.	1.6	2
154	Acute kidney injury following peripheral angiography and endovascular therapy: A systematic review of the literature. Catheterization and Cardiovascular Interventions, 2016, 88, 264-273.	0.7	50
155	Response to Letter Regarding Article, â€œAir Versus Oxygen in ST-Segmentâ€“Elevation Myocardial Infarctionâ€• Circulation, 2016, 133, e29.	1.6	5
156	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.3	238
157	Effect of supplemental oxygen exposure on myocardial injury in ST-elevation myocardial infarction. Heart, 2016, 102, 444-451.	1.2	34
158	Accuracy of Echocardiographic Cardiac Index Assessment in Subjects with Preserved Left Ventricular Ejection Fraction. Echocardiography, 2015, 32, 1628-1638.	0.3	17
159	Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy. Journal of Cardiac Surgery, 2015, 30, 871-873.	0.3	0
160	Augmented endothelial <scp>l</scp>â€arginine transport ameliorates pressureâ€overloadâ€induced cardiac hypertrophy. Experimental Physiology, 2015, 100, 796-804.	0.9	4
161	The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention. Catheterization and Cardiovascular Interventions, 2015, 86, 1228-1233.	0.7	14
162	Augmented Endothelial-Specific L-Arginine Transport Blunts the Contribution of the Sympathetic Nervous System to Obesity Induced Hypertension in Mice. PLoS ONE, 2015, 10, e0131424.	1.1	2

#	Article	IF	Citations
163	Air Versus Oxygen in ST-Segmentâ€"Elevation Myocardial Infarction. Circulation, 2015, 131, 2143-2150.	1.6	468
164	Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. , 2015, 154, 1-12.		35
165	Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. European Heart Journal Cardiovascular Imaging, 2015, 16, 14-22.	0.5	195
166	Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial. Journal of Cardiac Failure, 2015, 21, 594-600.	0.7	31
167	Long-term survival of adults with cardiogenic shock after venoarterial extracorporeal membrane oxygenation. Journal of Critical Care, 2015, 30, 949-956.	1.0	60
168	Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. International Journal of Cardiology, 2015, 187, 227-228.	0.8	30
169	Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression. Molecular Therapy, 2015, 23, 1211-1221.	3.7	18
170	Role of mitochondrial dysfunction in hyperglycaemia-induced coronary microvascular dysfunction: Protective role of resveratrol. Diabetes and Vascular Disease Research, 2015, 12, 208-216.	0.9	27
171	Management of Heart Failure With Preserved Ejection Fraction: A Review. Clinical Therapeutics, 2015, 37, 2186-2198.	1.1	30
172	Clinical utility of invasive exercise hemodynamic evaluation in LVAD patients. Journal of Heart and Lung Transplantation, 2015, 34, 1635-1637.	0.3	13
173	Cardio-protective effects of combined l-arginine and insulin: Mechanism and therapeutic actions in myocardial ischemia-reperfusion injury. European Journal of Pharmacology, 2015, 769, 64-70.	1.7	8
174	Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.3	503
175	CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS ONE, 2015, 10, e0133616.	1.1	39
176	Abnormal Mitochondrial L-Arginine Transport Contributes to the Pathogenesis of Heart Failure and Rexoygenation Injury. PLoS ONE, 2014, 9, e104643.	1.1	19
177	A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. European Heart Journal Cardiovascular Imaging, 2014, 15, 1108-1116.	0.5	77
178	Evaluating the Utility of Circulating Biomarkers of Collagen Synthesis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2014, 7, 271-278.	1.6	42
179	Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. European Journal of Heart Failure, 2014, 16, 796-801.	2.9	106
180	Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography. Catheterization and Cardiovascular Interventions, 2014, 83, 741-745.	0.7	12

#	Article	IF	Citations
181	Impaired Myocardial Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2014, 3, e001293.	1.6	47
182	Diffuse Myocardial Fibrosis Evaluated by Post-Contrast T1 Mapping Correlates With Left Ventricular Stiffness. Journal of the American College of Cardiology, 2014, 63, 1112-1118.	1.2	88
183	Effects of Healthy Aging on the Cardiopulmonary Hemodynamic Response to Exercise. American Journal of Cardiology, 2014, 114, 131-135.	0.7	52
184	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. Journal of Cardiac Failure, 2014, 20, 212-221.	0.7	111
185	Cardiogenic Genes Expressed in Cardiac Fibroblasts Contribute to Heart Development and Repair. Circulation Research, 2014, 114, 1422-1434.	2.0	188
186	Determinants and implications of elevated soluble ST2 levels in heart failure. International Journal of Cardiology, 2014, 176, 1242-1243.	0.8	9
187	Endothelial cationic amino acid transporter-1 overexpression blunts the effects of oxidative stress on pressor responses to behavioural stress in mice. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 1031-1037.	0.9	3
188	Device-Based Therapy in the Prevention of Contrast-Induced Nephropathy. Interventional Cardiology Clinics, 2014, 3, 421-428.	0.2	2
189	Regulation and actions of activin A and follistatin in myocardial ischaemiaâ€"reperfusion injury. Cytokine, 2014, 69, 255-262.	1.4	29
190	Iron Deficiency in Patients With Idiopathic Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2014, 23, 287-292.	0.2	42
191	Exploring which patients without return of spontaneous circulation following ventricular fibrillation out-of-hospital cardiac arrest should be transported to hospital?. Resuscitation, 2014, 85, 326-331.	1.3	36
192	Impact of Cardiac Magnetic Resonance Imaging. Circulation Journal, 2014, 79, 216-217.	0.7	3
193	Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 253-261.	0.9	15
194	Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm, 2013, 10, 1334-1339.	0.3	51
195	Does hypoxemia have an impact on the cardiac release and circulating concentrations of natriuretic peptides in humans in vivo?. International Journal of Cardiology, 2013, 167, 1046-1048.	0.8	2
196	Cardiac Imaging in FIP1L1-PDGFRA. Journal of the American College of Cardiology, 2013, 62, 1304.	1.2	1
197	Cellular Reprogramming. Circulation: Heart Failure, 2013, 6, 1102-1107.	1.6	2
198	Noninvasive Assessment of Pulmonary Vascular Resistance by Doppler Echocardiography. Journal of the American Society of Echocardiography, 2013, 26, 1170-1177.	1.2	141

#	Article	IF	Citations
199	Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure. European Journal of Heart Failure, 2013, 15, 292-298.	2.9	27
200	Integration of exercise evaluation into the algorithm for evaluation of patients with suspected heart failure with preserved ejection fraction. International Journal of Cardiology, 2013, 168, 716-722.	0.8	16
201	Extracorporeal Membrane Oxygenation to Support Cardiopulmonary Resuscitation in a Sheep Model of Refractory Ischaemic Cardiac Arrest. Heart Lung and Circulation, 2013, 22, 421-427.	0.2	17
202	Reperfusionâ€induced myocardial dysfunction is prevented by endogenous annexinâ€<scp>A</scp>1 and its <scp>N</scp>â€terminalâ€derived peptide <scp>A</scp>câ€<scp>ANX</scp>â€<scp>A</scp>1_{2â€26}. British Journal of Pharmacology, 2013, 168, 238-252.	2.7	53
203	Impact of N-acetylcysteine on Endothelial Function, B-type Natriuretic Peptide and Renal Function in Patients with the Cardiorenal Syndrome: A Pilot Cross Over Randomised Controlled Trial. Heart Lung and Circulation, 2013, 22, 256-259.	0.2	11
204	Cardiac Complications of Thoracic Irradiation. Journal of the American College of Cardiology, 2013, 61, 2319-2328.	1.2	310
205	Diffuse Ventricular Fibrosis Is a Late Outcome of Tachycardia-Mediated Cardiomyopathy After Successful Ablation. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 697-704.	2.1	56
206	Endothelial dysfunction in patients with type 2 diabetes post acute coronary syndrome. Diabetes and Vascular Disease Research, 2013, 10, 368-374.	0.9	12
207	Effect of Oxygen on Cardiac Differentiation in Mouse iPS Cells: Role of Hypoxia Inducible Factor-1 and Wnt/Beta-Catenin Signaling. PLoS ONE, 2013, 8, e80280.	1.1	37
208	Insulin-Mediated Activation of the L-Arginine Nitric Oxide Pathway in Man, and Its Impairment in Diabetes. PLoS ONE, 2013, 8, e61840.	1.1	26
209	Percutaneous re-circulating isolated limb perfusion of gentamicin in a large animal model: targeted delivery of gentamicin to limb. American Journal of Translational Research (discontinued), 2013, 5, 47-52.	0.0	1
210	Effect of Iron Chelation on Myocardial Infarct Size and Oxidative Stress in ST-Elevationâ€"Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 270-278.	1.4	81
211	Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. European Journal of Heart Failure, 2012, 14, 931-938.	2.9	260
212	Irregular Rhythm Adversely Influences Calcium Handling in Ventricular Myocardium. Circulation: Heart Failure, 2012, 5, 786-793.	1.6	59
213	Diffuse Ventricular Fibrosis in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 2402-2408.	1.2	131
214	Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiological Genomics, 2012, 44, 211-219.	1.0	83
215	A randomized controlled trial of oxygen therapy in acute myocardial infarction Air Verses Oxygen In myocarDial infarction study (AVOID Study). American Heart Journal, 2012, 163, 339-345.e1.	1.2	56
216	Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. International Journal of Cardiology, 2012, 155, 249-256.	0.8	35

#	Article	IF	Citations
217	Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 70.	1.6	120
218	Hemodynamic Determinants of the Abnormal Cardiopulmonary Exercise Response in Heart Failure With Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2012, 18, 702-710.	0.7	33
219	Atrial Electrical and Structural Remodeling Associated with Longstanding Pulmonary Hypertension and Right Ventricular Hypertrophy in Humans. Journal of Cardiovascular Electrophysiology, 2012, 23, 614-620.	0.8	72
220	Nitroxyl (HNO) Stimulates Soluble Guanylyl Cyclase to Suppress Cardiomyocyte Hypertrophy and Superoxide Generation. PLoS ONE, 2012, 7, e34892.	1.1	40
221	Nerve Growth Factor Stimulates Cardiac Regeneration via Cardiomyocyte Proliferation in Experimental Heart Failure. PLoS ONE, 2012, 7, e53210.	1.1	33
222	Augmentation of left ventricular mechanics by recirculationâ€mediated AAV2/1â€"SERCA2a gene delivery in experimental heart failure. European Journal of Heart Failure, 2011, 13, 247-253.	2.9	51
223	Advanced Glycation End Products Are Direct Modulators of Î²-Cell Function. Diabetes, 2011, 60, 2523-2532.	0.3	135
224	Myocardial Fibrosis Predicts Appropriate Device Therapy in Patients With Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2011, 57, 821-828.	1.2	279
225	Myocardial and Systemic Iron Depletion in Heart Failure. Journal of the American College of Cardiology, 2011, 58, 474-480.	1.2	135
226	NKX2-5eGFP/w hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nature Methods, 2011, 8, 1037-1040.	9.0	384
227	Accuracy of Doppler Echocardiography to Estimate Key Hemodynamic Variables in Subjects With Normal Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2011, 17, 405-412.	0.7	30
228	Temporal changes in diastolic function in heart failure patients with restrictive filling. International Journal of Cardiology, 2011, 146, 246-248.	0.8	1
229	Transcardiac gradients of B-type natriuretic peptides are increased in human pulmonary arterial hypertension. International Journal of Cardiology, 2011, 151, 117-119.	0.8	4
230	Atrial Electrical and Structural Changes Associated with Longstanding Hypertension in Humans: Implications for the Substrate for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 1317-1324.	0.8	129
231	Singleâ€unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover. Journal of Physiology, 2011, 589, 2597-2605.	1.3	53
232	Usefulness of Cooling and Coronary Catheterization to Improve Survival in Out-of-Hospital Cardiac Arrest. American Journal of Cardiology, 2011, 107, 522-527.	0.7	65
233	Post Cardiac Arrest Syndrome. Circulation, 2011, 123, 1428-1435.	1.6	245
234	Relation between QT interval variability and cardiac sympathetic activity in hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1412-H1417.	1.5	80

#	Article	IF	Citations
235	CXCR4 Antagonism Attenuates the Cardiorenal Consequences of Mineralocorticoid Excess. Circulation: Heart Failure, 2011, 4, 651-658.	1.6	57
236	Hospital characteristics are associated with patient outcomes following out-of-hospital cardiac arrest. Heart, 2011, 97, 1489-1494.	1.2	141
237	Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. Journal of Hypertension, 2010, 28, 780-788.	0.3	80
238	Delivery of Gene and Cellular Therapies for Heart Disease. Journal of Cardiovascular Translational Research, 2010, 3, 417-426.	1.1	11
239	Recirculating Delivery Improves Myocardial Cell Engraftment. Journal of Interventional Cardiology, 2010, 23, 14-17.	0.5	1
240	Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release. Hypertension, 2010, 56, 682-689.	1.3	64
241	Response to Does the Wall Stress Alone Stimulate the Natriuretic Peptide System?. Hypertension, 2010, 56, .	1.3	0
242	Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. European Journal of Heart Failure, 2010, 12, 45-51.	2.9	59
243	Myocardial Fibrosis in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2010, 363, 1971-1971.	13.9	3
244	Removal of Contrast Media From the Coronary Sinus Attenuates Renal Injury After Coronary Angiography and Intervention. Journal of the American College of Cardiology, 2010, 56, 525-526.	1.2	27
245	Hemodynamic Basis of Exercise Limitation in Patients With Heart Failure and Normal Ejection Fraction. Journal of the American College of Cardiology, 2010, 56, 855-863.	1.2	300
246	Bone Marrow-Derived Cells Contribute to Fibrosis in the Chronically Failing Heart. American Journal of Pathology, 2010, 176, 1735-1742.	1.9	94
247	High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus. Circulation, 2009, 119, 2103-2111.	1.6	363
248	Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation. Circulation, 2009, 120, 326-333.	1.6	336
249	Mechanistic insights into the link between a polymorphism of the 3â€²UTR of theSLC7A1gene and hypertension. Human Mutation, 2009, 30, 328-333.	1.1	61
250	Reduced <scp>L</scp>â€arginine transport contributes to the pathogenesis of myocardial ischemiaâ€reperfusion injury. Journal of Cellular Biochemistry, 2009, 108, 156-168.	1.2	23
251	Effect of peroxynitrite on endothelial L-arginine transport and metabolism. International Journal of Biochemistry and Cell Biology, 2009, 41, 2522-2527.	1.2	18
252	Protein kinase C mediated inhibition of endothelial l-arginine transport is mediated by MARCKS protein. Journal of Molecular and Cellular Cardiology, 2009, 46, 86-92.	0.9	10

#	Article	IF	Citations
253	Selective activation of the â€œbâ€•splice variant of phospholipase CÎ²1 in chronically dilated human and mouse atria. Journal of Molecular and Cellular Cardiology, 2009, 47, 676-683.	0.9	29
254	Recovery From Anthracycline Cardiomyopathy After Long-term Support With a Continuous Flow Left Ventricular Assist Device. Journal of Heart and Lung Transplantation, 2009, 28, 101-103.	0.3	31
255	Changes in Right Ventricular Function During Continuous-low Left Ventricular Assist Device Support. Journal of Heart and Lung Transplantation, 2009, 28, 360-366.	0.3	62
256	Heart Failure With Normal Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2009, 53, 905-918.	1.2	241
257	Microemboli and Microvascular Obstruction in Acute Coronary Thrombosis and Sudden Coronary Death. Journal of the American College of Cardiology, 2009, 54, 2167-2173.	1.2	158
258	B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target. Current Molecular Medicine, 2009, 9, 814-825.	0.6	30
259	Autonomic Control of the Aging Heart. NeuroMolecular Medicine, 2008, 10, 179-186.	1.8	77
260	Human Sympathetic Nerve Biology. Annals of the New York Academy of Sciences, 2008, 1148, 338-348.	1.8	84
261	Atrial Fibrillation Is Associated with Decreased Cardiac Sympathetic Response to Isometric Exercise in CHF in Comparison to Sinus Rhythm. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1125-1129.	0.5	11
262	CHRONIC MENTAL STRESS IS A CAUSE OF ESSENTIAL HYPERTENSION: PRESENCE OF BIOLOGICAL MARKERS OF STRESS. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 498-502.	0.9	134
263	Evaluation of Diffuse Myocardial Fibrosis in Heart Failure With Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping. Journal of the American College of Cardiology, 2008, 52, 1574-1580.	1.2	671
264	Initial Clinical Experience With the VentrAssist Left Ventricular Assist Device: The Pilot Trial. Journal of Heart and Lung Transplantation, 2008, 27, 479-485.	0.3	27
265	A Prospective, Multicenter Trial of the VentrAssist Left Ventricular Assist Device for Bridge to Transplant: Safety and Efficacy. Journal of Heart and Lung Transplantation, 2008, 27, 579-588.	0.3	83
266	Increased vascular endothelial growth factor mRNA in endomyocardial biopsies from allografts demonstrating severe acute rejection: A longitudinal study. Transplant Immunology, 2008, 18, 264-274.	0.6	16
267	Detrimental effect of oxidized LDL on endothelial arginine metabolism and transportation. International Journal of Biochemistry and Cell Biology, 2008, 40, 920-928.	1.2	17
268	The Synergism Between Atrial Fibrillation and Heart Failure. Journal of Cardiac Failure, 2008, 14, 320-326.	0.7	19
269	Tricuspid Regurgitation Contributes to Renal Dysfunction in Patients With Heart Failure. Journal of Cardiac Failure, 2008, 14, 824-830.	0.7	92
270	Elevated Brain Serotonin Turnover in Patients With Depression. Archives of General Psychiatry, 2008, 65, 38.	13.8	185

#	Article	IF	Citations
271	Reversing Advanced Heart Failure by Targeting Ca‹sup›2+‹/sup›Cycling. Annual Review of Medicine, 2008, 59, 13-28.	5.0	44
272	Impaired Pulmonary Diffusing Capacity and Hypoxia in Heart Failure Correlates With Central Sleep Apnea Severity*. Chest, 2008, 134, 67-72.	0.4	45
273	B-Type Natriuretic Peptide in End-Stage Renal Disease: A Neurohormone Rather Than a Volume Status Monitor. Southern Medical Journal, 2008, 101, 1081-1082.	0.3	0
274	Effect of Nitrous Oxide Anesthesia on Plasma Homocysteine and Endothelial Function. Anesthesiology, 2008, 109, 657-663.	1.3	83
275	Myocardial Ischemia-Reperfusion Injury, Antioxidant Enzyme Systems, and Selenium: A Review. Current Medicinal Chemistry, 2007, 14, 1539-1549.	1.2	234
276	Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: Reduction by a selective serotonin reuptake inhibitor. Stress, 2007, 10, 295-304.	0.8	48
277	Specific Serotonin Reuptake Inhibition in Major Depressive Disorder Adversely Affects Novel Markers of Cardiac Risk. Hypertension Research, 2007, 30, 285-293.	1.5	70
278	Identification of a Novel Polymorphism in the 3â€²UTR of thel-Arginine Transporter GeneSLC7A1. Circulation, 2007, 115, 1269-1274.	1.6	74
279	Sleep Apnea in Heart Failure Increases Heart Rate Variability and Sympathetic Dominance. Sleep, 2007, 30, 1509-1514.	0.6	60
280	Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. Journal of Hypertension, 2007, 25, 2117-2124.	0.3	259
281	Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace, 2007, 9, 751-756.	0.7	27
282	Antioxidant Therapy for Severe Cardiac Failure Induced by Iron Overload Secondary to Dyserythropoietic Anaemia. Heart Lung and Circulation, 2007, 16, 394-397.	0.2	2
283	Percutaneous Cardiac Recirculation-Mediated Gene Transfer of an Inhibitory Phospholamban Peptide Reverses Advanced Heart Failure in Large Animals. Journal of the American College of Cardiology, 2007, 50, 253-260.	1.2	136
284	Determination of plasma free 3-nitrotyrosine and tyrosine by reversed-phase liquid chromatography with 4-fluoro-7-nitrobenzofurazan derivatization. Biomedical Chromatography, 2007, 21, 273-278.	0.8	24
285	Drug discovery for heart failure: a new era or the end of the pipeline?. Nature Reviews Drug Discovery, 2007, 6, 127-139.	21.5	104
286	Prolonged cardiac allograft ischemic time ? no impact on long-term survival but at what cost?. Clinical Transplantation, 2007, 21, 321-329.	0.8	35
287	Subacute Anthracycline Cardiotoxicity. Heart Lung and Circulation, 2006, 15, 59-61.	0.2	12
288	Evaluation of Sympathetic Re-innervation in Heterotopic Cardiac Transplants by Iodine-123-Metaiodobenzylguanidine (I-123-MIBG) Imaging. Journal of Heart and Lung Transplantation, 2006, 25, 977-980.	0.3	9

#	Article	IF	Citations
289	Evidence for Increased Atrial Sympathetic Innervation in Persistent Human Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 821-829.	0.5	100
290	Endothelial Dysfunction and Impaired l-arginine Transport in Hypertension and Genetically Predisposed Normotensive Subjects. Trends in Cardiovascular Medicine, 2006, 16, 118-124.	2.3	23
291	Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of functional mitral regurgitation in patients with heart failure. Catheterization and Cardiovascular Interventions, 2006, 68, 205-210.	0.7	46
292	Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovascular Research, 2006, 72, 112-123.	1.8	75
293	Response to Cigarettes and ADMA: The Smoke Hasnâ€™t Cleared Yet. Hypertension, 2006, 48, .	1.3	0
294	Does Arginase Activity In Vitro Represent That In Vivo?. Hypertension, 2006, 48, E14; author reply E15.	1.3	0
295	Adverse Effects of Cigarette Smoke on NO Bioavailability. Hypertension, 2006, 48, 278-285.	1.3	149
296	Letter by Kaye and Esler Regarding Article â€œExtracardiac Progenitor Cells Repopulate Most Major Cell Types in the Transplanted Human Heartâ€• Circulation, 2006, 113, e844; author reply e845.	1.6	2
297	Sympathetic Nervous System Neuroplasticity. Hypertension, 2006, 47, 143-144.	1.3	8
298	The neuronal noradrenaline transporter, anxiety and cardiovascular disease. Journal of Psychopharmacology, 2006, 20, 60-66.	2.0	73
299	Biventricular pacing in heart failure: a review. Expert Review of Cardiovascular Therapy, 2006, 4, 97-109.	0.6	2
300	Angiotensin II and norepinephrine release: interaction and effects on the heart. Journal of Hypertension, 2005, 23, 1077-1082.	0.3	23
301	Augmentation of endothelial function following exercise training is associated with increased L-arginine transport in human heart failure. Clinical Science, 2005, 109, 523-530.	1.8	30
302	Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1359-H1365.	1.5	25
303	Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovascular Research, 2005, 66, 256-264.	1.8	96
304	Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure. European Heart Journal, 2005, 26, 2562-2567.	1.0	17
305	Left ventricular apical infection and rupture complicating left ventricular assist device explantation in 2 women with postpartum cardiomyopathy. Journal of Heart and Lung Transplantation, 2005, 24, 350-354.	0.3	5
306	First Clinical Implant of the VentrAssist Left Ventricular Assist System as Destination Therapy for End-Stage Heart Failure. Journal of Heart and Lung Transplantation, 2005, 24, 1150-1154.	0.3	44

#	Article	IF	Citations
307	Heart failure: how can we prevent the epidemic?. Medical Journal of Australia, 2004, 180, 143-143.	0.8	0
308	Impairedl-Arginine Transport and Endothelial Function in Hypertensive and Genetically Predisposed Normotensive Subjects. Circulation, 2004, 110, 3680-3686.	1.6	120
309	Percutaneous Mitral Annular Reduction Provides Continued Benefit in an Ovine Model of Dilated Cardiomyopathy. Circulation, 2004, 110, 3088-3092.	1.6	67
310	Sympathetic Augmentation in Hypertension. Hypertension, 2004, 43, 169-175.	1.3	451
311	In vivo and in vitro evidence for ACh-stimulated l-arginine uptake. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H395-H400.	1.5	10
312	Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E744-E752.	1.8	58
313	Cardiac Sympathetic Nerve Biology and Brain Monoamine Turnover in Panic Disorder. Annals of the New York Academy of Sciences, 2004, 1018, 505-514.	1.8	56
314	Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a time-controlled ortho-phthaldialdehyde precolumn derivatization. Analytical Biochemistry, 2004, 326, 87-92.	1.1	74
315	Controlled Trial of Continuous Positive Airway Pressure in Obstructive Sleep Apnea and Heart Failure. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 361-366.	2.5	564
316	Interaction between cardiac sympathetic drive and heart rate in heart failure. Journal of the American College of Cardiology, 2004, 44, 2008-2015.	1.2	45
317	Myocardial endothelin-1 release and indices of inflammation during angioplasty for acute myocardial infarction and stable coronary artery disease. American Heart Journal, 2004, 148, 341-347.	1.2	21
318	An age-related decline in endothelial function is not associated with alterations in l-arginine transport in humans. Journal of Hypertension, 2004, 22, 321-327.	0.3	19
319	??-Adrenoceptor-mediated, nitric-oxide-dependent vasodilatation is abnormal in early hypertension. Journal of Hypertension, 2004, 22, 1917-1925.	0.3	14
320	Continuous positive airway pressure decreases myocardial oxygen consumption in heart failure. Clinical Science, 2004, 106, 599-603.	1.8	28
321	Endogenous cardiac opioids: Enkephalins in adaptation and protection of the heart. Heart Lung and Circulation, 2003, 12, 178-187.	0.2	50
322	Low-dose atorvastatin therapy does not augment endothelial function in active hypercholesterolaemic males. British Journal of Clinical Pharmacology, 2003, 55, 212-215.	1.1	3
323	Review of the current management of atrial fibrillation. Expert Opinion on Pharmacotherapy, 2003, 4, 1889-1899.	0.9	0
324	Interactions Between Leptin and the Human Sympathetic Nervous System. Hypertension, 2003, 41, 1072-1079.	1.3	223

#	Article	IF	Citations
325	Raised Sympathetic Nerve Activity in Heart Failure and Central Sleep Apnea Is Due to Heart Failure Severity. Circulation, 2003, 107, 1396-1400.	1.6	143
326	Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy. Circulation, 2003, 108, 560-565.	1.6	393
327	l -Arginine Transport in Humans With Cortisol-Induced Hypertension. Hypertension, 2003, 41, 1336-1340.	1.3	13
328	Feasibility and Short-Term Efficacy of Percutaneous Mitral Annular Reduction for the Therapy of Heart Failure-Induced Mitral Regurgitation. Circulation, 2003, 108, 1795-1797.	1.6	138
329	Inhibition of the Norepinephrine Transporter by the Venom Peptide Ï‡-MrIA. Journal of Biological Chemistry, 2003, 278, 40317-40323.	1.6	60
330	Regional Sympathetic Effects of Low-Dose Clonidine in Heart Failure. Hypertension, 2003, 41, 553-557.	1.3	21
331	Is Very High Sympathetic Tone in Heart Failure a Result of Keeping Bad Company?. Hypertension, 2003, 42, 870-872.	1.3	6
332	Chronic atrial fibrillation does not influence the magnitude of sympathetic overactivity in patients with heart failure. European Heart Journal, 2003, 24, 1657-1662.	1.0	13
333	The Effect of Successful Heart Transplant Treatment of Heart Failure on Central Sleep Apnea *. Chest, 2003, 124, 1675-1681.	0.4	145
334	??-Adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics and Genomics, 2003, 13, 379-382.	5.7	137
335	Impact of Sleep Apnea on Sympathetic Nervous System Activity in Heart Failure. Chest, 2003, 123, 1119-1126.	0.4	101
336	The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis. Annals of Internal Medicine, 2003, 139, 186.	2.0	197
337	Increased Suicide Rate in the Middle-Aged and Its Association With Hours of Sunlight. American Journal of Psychiatry, 2003, 160, 793-795.	4.0	93
338	Clinical treatment regimens for chronic heart failure: a review. Expert Opinion on Pharmacotherapy, 2002, 3, 1569-1576.	0.9	5
339	Norepinephrine Turnover Is Increased in Suprabulbar Subcortical Brain Regions and Is Related to Whole-Body Sympathetic Activity in Human Heart Failure. Circulation, 2002, 105, 1031-1033.	1.6	52
340	The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R909-R916.	0.9	95
341	Reduced Myocardial and Systemicl-Arginine Uptake in Heart Failure. Circulation Research, 2002, 91, 1198-1203.	2.0	31
342	Neurohormonal assessment of cardiac function. Coronary Artery Disease, 2002, 13, 415-419.	0.3	0

#	Article	IF	Citations
343	Divergent effects of ANP and BNP in acute heart failure: evidence for a putative BNP-selective receptor?. Journal of Hypertension, 2002, 20, 1195-1201.	0.3	12
344	Exercise training increases arterial compliance in patients with congestive heart failure. Clinical Science, 2002, 102, 1-7.	1.8	61
345	Exercise training increases arterial compliance in patients with congestive heart failure. Clinical Science, 2002, 102, 1.	1.8	23
346	An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. Journal of Cardiac Failure, 2002, 8, 108-115.	0.7	34
347	Influence of ageing on the sympathetic nervous system and adrenal medulla at rest and during stress. Biogerontology, 2002, 3, 45-49.	2.0	33
348	Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. Journal of the American College of Cardiology, 2001, 37, 1246-1251.	1.2	63
349	Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. Journal of the American College of Cardiology, 2001, 37, 1221-1227.	1.2	206
350	The sympathetic neurobiology of essential hypertension: disparate influences of obesity, stress, and noradrenaline transporter dysfunction?. American Journal of Hypertension, 2001, 14, S139-S146.	1.0	69
351	Sympathetic nervous system and insulin resistance: from obesity to diabetes. American Journal of Hypertension, 2001, 14, S304-S309.	1.0	241
352	Î²-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet, The, 2001, 358, 1609-1610.	6.3	72
353	Improved outcomes from a comprehensive management system for heart failure. European Journal of Heart Failure, 2001, 3, 619-625.	2.9	50
354	Sympathetic Nerve Biology In Essential Hypertension. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 986-989.	0.9	119
355	Acute Effects of Continuous Positive Airway Pressure on Cardiac Sympathetic Tone in Congestive Heart Failure. Circulation, 2001, 103, 2336-2338.	1.6	116
356	Mechanisms of Carvedilol Action in Human Congestive Heart Failure. Hypertension, 2001, 37, 1216-1221.	1.3	19
357	Phenotypic Evidence of Faulty Neuronal Norepinephrine Reuptake in Essential Hypertension. Hypertension, 2000, 36, 824-829.	1.3	88
358	The â€˜adrenaline hypothesisâ€™ of hypertension revisited. Journal of Hypertension, 2000, 18, 717-723.	0.3	67
359	Nitric oxide mediated modulation of norepinephrine transport: identification of a potential target for S-nitrosylation. British Journal of Pharmacology, 2000, 130, 1060-1064.	2.7	27
360	Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Failure Reviews, 2000, 5, 17-25.	1.7	87

#	Article	IF	Citations
361	In Vivo and In Vitro Evidence for Impaired Arginine Transport in Human Heart Failure. Circulation, 2000, 102, 2707-2712.	1.6	62
362	Reduced Myocardial Nerve Growth Factor Expression in Human and Experimental Heart Failure. Circulation Research, 2000, 86, E80-4.	2.0	111
363	Sympathetic Nervous System Activation in Essential Hypertension, Cardiac Failure and Psychosomatic Heart Disease. Journal of Cardiovascular Pharmacology, 2000, 35, S1-S7.	0.8	193
364	Leptin Is Released from the Human Brain: Influence of Adiposity and Gender1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2270-2274.	1.8	101
365	Influence of Pulmonary Capillary Wedge Pressure on Central Apnea in Heart Failure. Circulation, 1999, 99, 1574-1579.	1.6	420
366	EXPRESSION AND REGULATION OF THE SODIUM-CALCIUM EXCHANGER IN CARDIAC MICROVASCULAR ENDOTHELIAL CELLS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 651-655.	0.9	15
367	Catechol-O-methyltransferase activity in CHO cells expressing norepinephrine transporter. British Journal of Pharmacology, 1999, 128, 774-780.	2.7	9
368	Antiadrenergic effect of chronic amiodarone therapy in human heart failure. Journal of the American College of Cardiology, 1999, 33, 1553-1559.	1.2	34
369	Activation of Nitric Oxide Synthase (NOS3) by Mechanical Activity Alters Contractile Activity in a Ca2+-Independent Manner in Cardiac Myocytes: Role of Troponin I Phosphorylation. Biochemical and Biophysical Research Communications, 1999, 256, 398-403.	1.0	35
370	Human obesity is associated with a chronic elevation in brain 5-hydroxytryptamine turnover. Clinical Science, 1999, 96, 191-197.	1.8	24
371	Neural mechanisms in human obesity-related hypertension. Journal of Hypertension, 1999, 17, 1125-1133.	0.3	314
372	RESTORATION OF NITRIC OXIDE FUNCTION IN HUMAN HYPERLIPIDAEMIA, CONGESTIVE HEART FAILURE AND LIVER CIRRHOSIS. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 645-652.	0.9	3
373	Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. Journal of the Autonomic Nervous System, 1998, 72, 210-219.	1.9	70
374	Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet, The, 1998, 351, 879.	6.3	65
375	The failing human heart does not release nitrogen oxides. Life Sciences, 1998, 62, 883-887.	2.0	11
376	Differential Effect of Acute Baroreceptor Unloading on Cardiac and Systemic Sympathetic Tone in Congestive Heart Failure. Journal of the American College of Cardiology, 1998, 31, 583-587.	1.2	59
377	Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H906-H916.	1.5	54
378	Regulation by cAMP of Post-translational Processing and Subcellular Targeting of Endothelial Nitric-oxide Synthase (Type 3) in Cardiac Myocytes. Journal of Biological Chemistry, 1997, 272, 11198-11204.	1.6	44

#	Article	IF	Citations
379	Adrenergic Nervous System in Heart Failure. American Journal of Cardiology, 1997, 80, 7L-14L.	0.7	209
380	Region-Specific Neuropeptide Y Overflows at Rest and During Sympathetic Activation in Humans. Hypertension, 1997, 29, 137-143.	1.3	85
381	The role of the NO pathway in the control of cardiac function. Journal of Cardiac Failure, 1996, 2, S141-S147.	0.7	21
382	Dietary supplementation with l-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. Journal of the American College of Cardiology, 1996, 27, 1207-1213.	1.2	64
383	Cardiac Sympathetic Nerve Function in Congestive Heart Failure. Circulation, 1996, 93, 1667-1676.	1.6	376
384	Frequency-Dependent Activation of a Constitutive Nitric Oxide Synthase and Regulation of Contractile Function in Adult Rat Ventricular Myocytes. Circulation Research, 1996, 78, 217-224.	2.0	75
385	Abnormalities of the Autonomic Nervous System in Heart Failure. Cardiology in Review, 1995, 3, 184-195.	0.6	3
386	Regional Sympathetic Nervous Activation after a Large Meal in Humans. Clinical Science, 1995, 89, 145-154.	1.8	91
387	Nitric Oxide-dependent Parasympathetic Signaling Is Due to Activation of Constitutive Endothelial (Type III) Nitric Oxide Synthase in Cardiac Myocytes. Journal of Biological Chemistry, 1995, 270, 14582-14586.	1.6	331
388	Regional origins of 3-methoxy-4-hydroxyphenylglycol in plasma: effects of chronic sympathetic nervous activation and denervation, and acute reflex sympathetic stimulation. Journal of the Autonomic Nervous System, 1995, 55, 169-178.	1.9	29
389	Fallibility of plasma noradrenaline measurements in studying postprandial sympathetic nervous responses. Journal of the Autonomic Nervous System, 1995, 56, 97-104.	1.9	23
390	Central Nervous System Norepinephrine Turnover in Essential Hypertension. Annals of the New York Academy of Sciences, 1995, 763, 679-694.	1.8	11
391	Adverse consequences of high sympathetic nervous activity in the failing human heart. Journal of the American College of Cardiology, 1995, 26, 1257-1263.	1.2	614
392	Effects of Aging on the Responsiveness of the Human Cardiac Sympathetic Nerves to Stressors. Circulation, 1995, 91, 351-358.	1.6	151
393	Increased Central Nervous System Monoamine Neurotransmitter Turnover and Its Association With Sympathetic Nervous Activity in Treated Heart Failure Patients. Circulation, 1995, 92, 1813-1818.	1.6	70
394	Monoaminergic Neuronal Activity in Subcortical Brain Regions in Essential Hypertension. Blood Pressure, 1994, 3, 55-66.	0.7	31
395	LOW CHOLESTEROL AND IMPAIRED CARDIAC FUNCTION FOLLOWING HEART TRANSPLANTATION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 659-661.	0.9	0
396	EVIDENCE FOR IMPAIRED ENDOTHELIUM DEPENDENT VASODILATION IN EXPERIMENTAL LEFT VENTRICULAR DYSFUNCTION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 709-719.	0.9	14

#	Article	IF	Citations
397	Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. Journal of the American College of Cardiology, 1994, 23, 570-578.	1.2	274
398	Effects of dietary marine oil supplementation on reactivity of human buttock subcutaneous arteries and forearm veins in vitro. British Journal of Pharmacology, 1994, 112, 566-570.	2.7	11
399	Electrocardiographic and echocardiographic features of left atrial size after orthotopic cardiac transplantation. American Journal of Cardiology, 1992, 70, 1096-1099.	0.7	9